Chang, Han

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 2,503

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 2,401

A Landscape of Pharmacogenomic Interactions in Cancer

Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 2,090

Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab

Baxi, V., Lee, G., Duan, C., Pandya, D., Cohen, D. N., Edwards, R., Chang, H., Li, J., Elliott, H., Pokkalla, H., et al. (2022) · Modern Pathology

Cancer Immunotherapy and BiomarkersAI in cancer detection

Cited by 66